Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management repeatedly redirects attention away from conventional measure/storyline and toward different part already earning, and indicates record not caught up. Company Surmodics. Conventional judged? Likely overall revenue/earnings, medical device coatings royalties? They have two segments: Medical Device and IVD. They are developing whole product solutions (drug-coated balloons, catheters). On call, management discusses strong quarter, revenue growth, SurVeil agreement with Abbott, R&D pipeline, Embolitech acquisition, IVD launch. Need see if they set aside conventional yardstick and point to different part already earning. Question asks: "On this call, does management REPEATEDLY REDIRECT ATTENTION AWAY FROM THE MEASURE OR STORYLINE BY WHICH THE COMPANY IS CONVENTIONALLY JUDGED and toward a DIFFERENT PART OF THE BUSINESS that it says is ALREADY EARNING TODAY — and does management indicate that this different part is not yet what the company's reported results or outside understanding reflect?" Need identify conventional yardstick. Surmodics historically? Medical device coatings royalties? They have "core business" and "whole product solutions" pipeline. Management talks about "underlying core business performed well" and "continue to execute on core commercial opportunities." They update guidance. They emphasize "whole product solutions" strategy, "proprietary products" with potential partners. But are they redirecting away from conventional measure? Maybe conventional judged by "royalty and license fee revenue" from coatings? They report strong royalty revenue. They also highlight product sales growth 49% due to balloon catheter unit volume. They talk about "whole product solutions" as future. But is it already earning? They have products with regulatory clearance but not yet significant revenue? They mention Telemark microcatheter, .014 PTA balloon, .018 balloon. They are "undergoing clinical evaluation" and "targeting revenue generation for this product in fiscal 2019." So not already earning? They have product sales increased due to balloon catheter unit volume from customer product launches, but that's coatings? Need parse.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.